Join Growin Stock Community!

Fulgent genetics, inc.FLGT.US Overview

US StockHealthcare
(No presentation for FLGT)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

FLGT AI Insights

FLGT Overall Performance

FLGT AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

FLGT Recent Performance

-4.92%

Fulgent genetics, inc.

0.05%

Avg of Sector

-0.31%

S&P500

FLGT PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

FLGT Key Information

FLGT Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

FLGT Profile

Fulgent Genetics, Inc., together with its subsidiaries, provides COVID-19, molecular diagnostic, and genetic testing services to physicians and patients in the United States and internationally. The company offers genetic tests comprising Focus and Comprehensive oncology panels tests; Beacon carrier screening panels test for inherited conditions; solid tumor molecular profiling for somatic cancer testing; rapid whole genome testing for children in NICU and PICU; newborn genetic analysis panel; single front-line test to detect ataxia-related variants and repeat expansions through sequencing; picture genetics, a patient-initiated genetic testing; whole exome and clinical exome panel tests; whole genome, mutation, and repeat expansion testing services, as well as research service tests. It also provides next generation sequencing and reverse transcription polymerase chain reaction-based tests, as well as antigen-based diagnostic tests for the detection of SARS-CoV-2. In addition, the company offers flow cytometry, a cell analysis technique providing diagnosis, prognosis, and monitoring of malignancies; fluorescence in-situ hybridization for detecting and locating a specific DNA sequence on a chromosome; immunohistochemistry, an imaging technique used to visualize antigens in cells; cytogenetics, which analyzes the chromosome set for numerical and structural abnormalities; and molecular testing that includes hematopoietic and solid tumor molecular assays. The company serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients. Fulgent Genetics has strategic partnership with Helio Health, Inc. to commercialize blood-based early cancer detection tests. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in Temple City, California.

Price of FLGT

FLGT FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

FLGT Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.96
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
1.50
PB Ratio
0.42
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
40.56%
Net Margin
-18.75%
Revenue Growth (YoY)
13.83%
Profit Growth (YoY)
22.07%
3-Year Revenue Growth
7.17%
3-Year Profit Growth
35.88%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.96
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
1.50
PB Ratio
0.42
Price-to-FCF
-
Gross Margin
40.56%
Net Margin
-18.75%
Revenue Growth (YoY)
13.83%
Profit Growth (YoY)
22.07%
3-Year Revenue Growth
7.17%
3-Year Profit Growth
35.88%

  • When is FLGT's latest earnings report released?

    The most recent financial report for Fulgent genetics, inc. (FLGT) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating FLGT's short-term business performance and financial health. For the latest updates on FLGT's earnings releases, visit this page regularly.

  • What is the operating profit of FLGT?

    According to the latest financial report, Fulgent genetics, inc. (FLGT) reported an Operating Profit of -36.24M with an Operating Margin of -43.48% this period, representing a decline of 124.59% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is FLGT's revenue growth?

    In the latest financial report, Fulgent genetics, inc. (FLGT) announced revenue of 83.34M, with a Year-Over-Year growth rate of 9.34%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much cash does FLGT have?

    At the end of the period, Fulgent genetics, inc. (FLGT) held Total Cash and Cash Equivalents of 50.19M, accounting for 0.04 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does FLGT go with three margins increasing?

    In the latest report, Fulgent genetics, inc. (FLGT) did not achieve the “three margins increasing” benchmark, with a gross margin of 39.1%%, operating margin of -43.48%%, and net margin of -28.1%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess FLGT's profit trajectory and future growth potential.

  • Is FLGT's EPS continuing to grow?

    According to the past four quarterly reports, Fulgent genetics, inc. (FLGT)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -0.76. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of FLGT?

    Fulgent genetics, inc. (FLGT)'s Free Cash Flow (FCF) for the period is -83.12M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 491.35% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of FLGT?

    The latest valuation data shows Fulgent genetics, inc. (FLGT) has a Price-To-Earnings (PE) ratio of -7.91 and a Price/Earnings-To-Growth (PEG) ratio of -0.03. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.